Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma

Nuebel, Charlotte; Amaral, Teresa; Leiter, Ulrike; Flatz, Lukas; Forschner, Andrea

dc.contributor.author	Amaral, Teresa
dc.contributor.author	Flatz, Lukas
dc.contributor.author	Nübel, Charlotte
dc.contributor.author	Leiter-Stöppke, Ulrike
dc.contributor.author	Forschner, Andrea Lydia
dc.date.accessioned	2024-02-20T09:45:12Z
dc.date.available	2024-02-20T09:45:12Z
dc.date.issued	2023
dc.identifier.issn	2234-943X
dc.identifier.uri	http://hdl.handle.net/10900/151183
dc.language.iso	en	de_DE
dc.publisher	Lausanne : Frontiers Media Sa	de_DE
dc.relation.uri	http://dx.doi.org/10.3389/fonc.2023.1256800	de_DE
dc.subject.ddc	610	de_DE
dc.title	Outcome and treatment-related adverse events of combined immune checkpoint inhibition with flipped dosing in a real-world cohort of 79 patients with metastasized melanoma	de_DE
dc.type	Article	de_DE
utue.quellen.id	20240124000000_00304
utue.personen.roh	Nuebel, Charlotte
utue.personen.roh	Amaral, Teresa
utue.personen.roh	Leiter, Ulrike
utue.personen.roh	Flatz, Lukas
utue.personen.roh	Forschner, Andrea
dcterms.isPartOf.ZSTitelID	Frontiers in Oncology	de_DE
dcterms.isPartOf.ZS-Issue	Article 1256800	de_DE
dcterms.isPartOf.ZS-Volume	13	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE